AVAILABLE FOR PUBLIC DISCLOSURE WITHOUT REDACTION Page: 2 of

First Page		Document Content
Gadolinium Nephrogenic systemic fibrosis Gadodiamide Magnetic resonance imaging Pentetic acid Contrast medium Gadoteridol Gadoversetamide Schering AG Chemistry Matter Gadopentetic acid		AVAILABLE FOR PUBLIC DISCLOSURE WITHOUT REDACTION Page: 2 of Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 2,13 MB Share Document on Facebook

	Contrast enhancement in MR imaging: New options, new techniques, new opportunities Nephrogenic systemic fibrosis update 2014: Fact versus theory Emanuel Kanal, MD, FACR, FISMRM DocID: 1g70b - View Document
	[removed] ® HIGHLIGHTS OF PRESCRIBING INFORMATION DocID: Wwpb - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OMNISCAN safely and effectively. See full prescribing information for OMNISCAN. OMNISCANTM (gadodiamide) Injection f DocID: LwKY - View Document
	OPTIMARK (gadoversetamide) injection Label DocID: KSKv - View Document
	FDA Patient Safety News: Show #54, August 2006 DocID: HDJ2 - View Document